The leading drug in this class of product is talimogene laherparepvec (Imlygic), an attenuated herpes simplex virus (HSV) encoding the human granulocyte-macrophage colony-stimulating factor (GM-CSF), used to treat unresectable melanoma with metastatic lesions (3). The gene discussed is CSF2; the disease is melanoma.